Disclaimer
This Guideline a empts to define principles of prac ce that should produce high-quality
pa ent care. It is applicable to specialists, primary care providers and ancillary healthcare
providers. This Guideline should not be considered exclusive of other methods of care
reasonably directed at obtaining the same results. The ul mate judgment concerning the
propriety of any course of conduct must be made by the clinician a er considera on of each
individual pa ent situa on.
Neither IGC, SITC, nor the authors endorse any product or service associated with the
distributor of this clinical reference tool.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2017 All rights reserved
SITCBLAD1793c
Defini on of Evidence Grades
Level Defini on
A Strong suppor ng evidence-based data from prospec ve, randomized,
controlled trials, meta-analyses, long-term follow-up of prospec ve,
uncontrolled trials
B Moderate suppor ng data from uncontrolled, prospec ve clinical trials
C Weak suppor ng data from retrospec ve reviews and case reports
Percentages Propor on of Task Force members favoring recommenda on
Abbrevia ons
AUA, American Urologic Associa on; BCG, Bacillus Calme e-Guérin; CIS, carcinoma in
situ; DDMVAC, dose-dense methotrexate, vinblas ne, doxorubicin, and cispla n; dMMR,
mismatch repair-deficient; EAU, European Associa on of Urology; FDA, U.S. Food and
Drug Administra on; IBCG, Interna onal Bladder Cancer Group; ICUD, Interna onal
Consulta on on Urological Diseases; MSI-H, Microsatellite instability-high; NAM,
Na onal Academy of Medicine; NCCN, Na onal Comprehensive Cancer Network; NMIBC,
non-muscle invasive bladder cancer; SITC, Society for Immunotherapy of Cancer; TUR,
transurethral resec on
Source
Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky
MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA
3rd, Abraham P, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement
on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017
Aug 15;5(1):68.
Lamm DL, Blumenstein BA, Crissman JD, Mon e JE, Go esman JE, Lowe BA, et al.
Maintenance bacillus Calme e-Guérin immunotherapy for recurrent Ta,T1 and carcinoma
in situ TCC of the bladder: A randomized SWOG study. J Urol. 2000;163:1124–9. PMID:
10737480
